The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications
about
Perspectives on anti-CD47 antibody treatment for experimental cancerInterplay between Cellular and Molecular Inflammatory Mediators in Lung CancerRethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerCancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistanceHarnessing immunosurveillance: current developments and future directions in cancer immunotherapyStructures of CD200/CD200 Receptor Family and Implications for Topology, Regulation, and EvolutionPolymorphisms in the Human Inhibitory Signal-regulatory Protein Do Not Affect Binding to Its Ligand CD47Lymphoma: immune evasion strategiesCD47 expression in cryopreserved equine cutaneous masses and normal skinDissection of agonistic and blocking effects of CD200 receptor antibodiesTranscriptome sequencing of tumor subpopulations reveals a spectrum of therapeutic options for squamous cell lung cancerCD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humansSplenic Dendritic Cells Survey Red Blood Cells for Missing Self-CD47 to Trigger Adaptive Immune Responses.Antibody Therapies in Cancer.Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells.Competing views on cancer.Macrophages in multiple myeloma: emerging concepts and therapeutic implications.An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patientsSilencing of CD47 and SIRPα by Polypurine reverse Hoogsteen hairpins to promote MCF-7 breast cancer cells death by PMA-differentiated THP-1 cellsEngagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cells.Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.Pathway-gene identification for pancreatic cancer survival via doubly regularized Cox regressionExploiting light chains for the scalable generation and platform purification of native human bispecific IgG.CD47 regulates the phagocytic clearance and replication of the Plasmodium yoelii malaria parasiteTherapeutic targeting of the thrombospondin-1 receptor CD47 to treat liver cancer.CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting CellsCD47 Promotes Protective Innate and Adaptive Immunity in a Mouse Model of Disseminated Candidiasis.Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.Loss of Cell Surface CD47 Clustering Formation and Binding Avidity to SIRPα Facilitate Apoptotic Cell Clearance by MacrophagesAnti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo.A fully human anti-CD47 blocking antibody with therapeutic potential for cancerMolecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals.A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cellsOriginal insights on thrombospondin-1-related antireceptor strategies in cancer.Development of anti-CD47 single-chain variable fragment targeted magnetic nanoparticles for treatment of human bladder cancer.Detecting cell-in-cell structures in human tumor samples by E-cadherin/CD68/CD45 triple staining.Photodynamic-therapy Activates Immune Response by disrupting Immunity Homeostasis of Tumor Cells, which Generates Vaccine for Cancer TherapySecreted Thrombospondin-1 Regulates Macrophage Interleukin-1β Production and Activation through CD47.Immunoregulatory CD4(-)CD8(-) T cells as a potential therapeutic tool for transplantation, autoimmunity, and cancer.
P2860
Q24602779-1A87212D-768F-4EEF-BD37-F399928399FEQ26768652-C8689AEB-E284-464B-9896-0C14957B2C58Q26780387-2671FB7E-11AA-4420-BCBD-4AA2E727BB93Q26829987-B889B518-9BAC-40F4-BFB1-D4CB6C81E8F3Q27021570-3D71AA58-FE1D-40BE-B004-4C67FAB6CAEEQ27677459-F5BEB028-4D13-4468-8EDF-36EFC16BA028Q27681812-EB38C6C1-974E-4849-A4B9-87F96BCB7FEDQ28080705-4528FF76-1C21-4AA1-BD48-DA90CC046DDAQ28275412-D763B1B5-253D-4CBE-8432-6DF38D673F35Q28488034-8F98C099-9221-4C8C-9DFC-E1D0D00C58C1Q28488566-90DEE2C4-A471-492F-9AA7-97AF884112EDQ28543785-D4848D8D-978B-49A5-9599-7493A2555096Q30670402-B3BACD83-03F7-4317-89C6-8EE3DD5D2E74Q31104000-B9D4D6AB-2021-437D-B47E-ABC2F58408E3Q33586204-19E66976-107C-4AE5-8B27-78DD9492B3F0Q34060169-F34D90F6-9FF2-4A8F-A605-F107F8494ACAQ34329242-FAC15477-FEAC-4DFB-ADDB-05C5934EE087Q34361976-D033202E-2CDD-4116-998B-54F40B1A40CBQ34483478-0B9C32FC-949A-4FAB-A165-E595B74E1907Q34541210-ECBCBB11-D720-412A-B4C0-E981E0FBC031Q34548156-D636C71F-1ED6-4A69-B9A1-431C7691D02AQ34553348-2EFA12FB-226B-4404-8C0C-3CCADE7C7CAEQ35102086-3239ABF7-6297-4BA3-A3EF-C4412ECD8B9BQ35119802-063033A4-0E30-428D-9078-D10B4AA2377EQ35189895-1CB3F51B-F057-4EFF-979B-0756EB626762Q35554493-6391C266-E348-4B75-834A-8BF953BCEF43Q35563107-DB5CF161-8BD2-47A3-BE63-C9599BB6B74CQ35648733-CB4CF0DC-0181-4D7B-9497-A2F5F0E7C986Q35781873-75319CF8-598C-43E4-A57F-118059425D72Q35815741-A5667C5F-EB2F-4E24-AC15-D1EE6C2A58F0Q35993525-5F562932-6A5D-47DC-A38F-8471E3A8C67AQ36198093-9D8198F3-E3A0-41BD-8472-4C57F4CED3F5Q36208486-5E95395C-4FD8-4475-8A44-F4A3D963231FQ36216038-E9147690-413B-44FF-B7C6-388B303F19D3Q36221374-301C3216-D553-43D4-8AE0-1CE6F8CFCB5FQ36276770-720F874F-A85E-4ABA-A98D-2DC5DF50DEEFQ36299664-558D430D-12AE-4DCC-891A-D2E93BFB4BF6Q36372462-8134C8AE-89F8-469F-8774-30128672E688Q36507239-D9D8AC7B-67B3-4512-808A-B980F420CDA2Q36557519-C4B2A23B-352B-47C3-B7A2-CB40706AD8BA
P2860
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications
@ast
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications
@en
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications
@nl
type
label
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications
@ast
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications
@en
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications
@nl
prefLabel
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications
@ast
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications
@en
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications
@nl
P2093
P2860
P3181
P1476
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications
@en
P2093
Irving L Weissman
Mark P Chao
Ravindra Majeti
P2860
P304
P3181
P356
10.1016/J.COI.2012.01.010
P407
P577
2012-04-01T00:00:00Z